Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Everspin Technologies Q4 2025 Earnings Call - MRAM Production Ramps, NOR Flash Replacement Talks Accelerate
Everspin closed Q4 with steady top-line execution, stronger product sales, and a clear product roadmap that shifts the company from niche supplier toward mainstream embedded non-volatile memory. The q...
- Q4 revenue of $14.8 million, up 12% year-over-year, and non-GAAP EPS of $0.11 per share, near the top of guidance.
- MRAM product sales were $13.5 million in Q4, up 22% year-over-year, showing product-led growth versus one-off licensing.
- Everspin recognized $2.0 million of other income in Q4, and has recorded $10.5 million to date under a $14.6 million DoD sustainment contract for onshore MRAM manufacturing, with estimated completion in H1 2027.
- +13 more takeaways
Stem Inc. Q4 2025 Earnings Call - Software-first turnaround delivers first full-year positive adjusted EBITDA and primes PowerTrack EMS for 2027 scale
Stem closed 2025 as a materially different company. Management pushed the business into a software and services focus, grew core software, services and Edge hardware revenue 25% to $141 million, and d...
- Stem declared 2025 a strategic turnaround year, shifting decisively toward a software-centric model and away from battery hardware resale.
- Full year 2025 revenue was $156 million, up 8% year-over-year, with software, services and Edge hardware at $141 million, up 25% year-over-year.
- PowerTrack-related ARR finished 2025 at $61 million, up 16% year-over-year and up 1% sequentially.
- +12 more takeaways
Cardlytics Q4 FY2025 Earnings Call - Reset to self-sustainability despite Bank of America exit and near-term supply headwinds
Cardlytics spent 2025 resetting the company: trimming costs, modernizing the tech stack, and positioning the business to be self-sustaining in 2026. The company closed out the year with positive adjus...
- Cardlytics completed a strategic reset in 2025 focused on cost discipline, product simplification, and balance sheet repair to reach self-sustainability in 2026.
- Fiscal 2025 billings were $385.0 million, down 13.3% year-over-year; revenue was $233.0 million, down 16.2% year-over-year.
- Annual Adjusted EBITDA was positive $10.1 million, up $7.5 million year-over-year, marking the third consecutive year of positive adjusted EBITDA.
- +17 more takeaways
AEO Inc. Fourth Quarter 2025 Earnings Call - Aerie and OFFLINE Power a Strong Finish Despite $130M of Tariff Headwinds
AEO closed 2025 with a decisive second-half rebound, led by Aerie and OFFLINE which together delivered outsized comps and margin leverage, offsetting heavy tariff pressure. Q4 revenue hit a record $1....
- Q4 revenue was a record $1.8 billion, up 10% year over year, with consolidated comps +8%.
- Aerie and OFFLINE drove the quarter, with Aerie/OFFLINE comps up 23% and OFFLINE described as one of the fastest growing brands in company history.
- Adjusted operating income in Q4 was $180 million, up 27% from $142 million a year ago, adjusted operating margin rose to 10.2% from 8.9%.
- +13 more takeaways
Verastem Oncology Q4 2025 Earnings Call - Commercial launch gains traction with $30.9M revenue since approval, VS-7375 advanced toward registration-directed trials
Verastem closed 2025 as a newly commercial company after FDA approval of the avutometinib plus defactinib CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer. Since approval in May, May...
- Verastem became a commercial-stage company in 2025 following FDA approval of avutometinib plus defactinib CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer, with approval delivered nearly two months ahead of the PDUFA date.
- Net product revenue for the launch period May through December 2025 was $30.9 million, including $17.5 million in Q4 2025, signaling early commercial traction.
- Nearly 300 prescribers had written scripts through February 2026, prescriptions split roughly 60/40 GynOnc to MedOnc, and more than half of prescriptions originate in academic centers.
- +12 more takeaways
MicroVision Q4 2025 Earnings Call - Acquisitions accelerate Lidar 2.0 shift, guiding $10M-$15M revenue and $65M-$70M cash burn in 2026
MicroVision used the Q4 and full-year 2025 call to reposition itself as a consolidated lidar vendor for automotive, industrial, and security and defense, leaning on recent Luminar and Scantinel acquis...
- Strategic pivot to 'Lidar 2.0': MicroVision says industry is moving from hardware-spec races to value-driven, software-enabled, design-to-cost solutions focused on scalable deployments across multiple end markets.
- Material acquisitions: Luminar and Scantinel were highlighted as transformational, adding Iris and Halo long-range products, a 1550 nm FMCW capability, and about 30 new Luminar customer relationships.
- Product portfolio breadth: MicroVision now claims a full-stack portfolio spanning MOVIA short-range sensors (MOVIA L and MOVIA S), Iris and Halo long-range sensors, 1550 nm FMCW from Scantinel, plus MOSAIK and Sentinel software for perception and point-cloud processing.
- +13 more takeaways
Alto Ingredients Q4 2025 Earnings Call - Strategic realignment lifts margins, CO2 and 45Z tailwinds
Alto delivered a clear rebound in 2025, turning a multi-year loss into positive earnings by tightening costs, optimizing assets, and leaning into CO2 and premium export markets. Q4 net income swung to...
- Q4 2025 net income attributable to common stockholders was $21.5 million, about $0.28 per diluted share, a roughly $63.5 million improvement versus Q4 2024.
- Adjusted EBITDA for Q4 was $27.9 million, and for full-year 2025 was $44.7 million, up approximately $35.6 million and $53.2 million year over year respectively.
- Primary drivers of improvement were stronger crush margins (+$0.15 per gallon year over year, contributing about $8 million), higher renewable fuel export sales (about $5 million), sale of Oregon carbon credits ($2.9 million), and staffing reductions (about $2.6 million).
- +12 more takeaways
Grocery Outlet Fourth Quarter 2025 Earnings Call - Leadership Owns Unacceptable Q4; Rebuilds Opportunistic Mix, Closes 36 Stores
Grocery Outlet did not hide the damage. Management called the fourth quarter unacceptable, took responsibility, and laid out a blunt turnaround: restore the opportunistic product flow that defines the...
- CEO Jason Potter said Q4 results were unacceptable and he owns fixing them, signaling accountability at the top.
- Comparable store sales declined 80 basis points in Q4 excluding an extra 53rd week; average transaction size fell 170 basis points while traffic rose 90 basis points.
- Q4 net sales were $1.22 billion, including $82.4 million from a 53rd week; excluding that week, revenue rose 3.2% year over year driven by new stores but offset by comps decline.
- +12 more takeaways
OmniAb Q4 2025 Earnings Call - Partner Pipeline Matures, OmniUltra and xPloration Drive New Growth
OmniAb closed 2025 with clear scale in its partner business and two fresh commercial plays. The company finished the year with 107 partners and 407 active programs, a meaningful uptick in new program ...
- Partner scale: OmniAb ended 2025 with 107 partners and 407 active programs, a net increase of 44 programs for the year.
- Program additions and attrition: 84 program additions in 2025, 40 terminations, and 25 program advancement events including 16 discovery->preclinical and 4 preclinical->phase 1 moves.
- Clinical traction: 32 active clinical and approved products at year-end, and 1 program reached the registration stage during 2025.
- +12 more takeaways
Pulmonx Q4 2025 Earnings Call - CEO Returns, Re-focuses Sales Force and Cuts Costs to Drive U.S. Rebound
Pulmonx ended 2025 with mixed results, management says the shortfall was largely self-inflicted and the fix is internal. Revenue in Q4 fell to $22.6 million, down 5% year over year, while full-year re...
- CEO Glen French returned and conducted a line-by-line review, concluding 2025 underperformance was largely due to internal execution and organizational choices rather than market collapse.
- Total worldwide revenue in Q4 2025 was $22.6 million, down 5% year over year; full-year revenue was $90.5 million, up 8% from 2024.
- U.S. revenue in Q4 was $14.1 million, an 11% decline versus prior year; U.S. full-year revenue was $57 million, up 1% year over year.
- +12 more takeaways